In contrast, the combination of Amy-F + RT results in a profound decrease in the CD4 and CD80 expression, and an increase in the CD8 and NKG2D expression in MCF-7 and MDA cells compared to Amy-F and RT groups, suggesting that the preemptive treatment with Amy-F prior to RT could hinder the excessive metabolic activity associated with immunomodulatory in both subtypes of BC cells. The gene discussed is KLRK1; the disease is breast cancer.